Asati V, Mahapatra DK, Bharti SK (2016) PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem 109:314–341

Article  PubMed  CAS  Google Scholar 

Baek S et al (2012) Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc 134(1):103–106

Article  PubMed  CAS  Google Scholar 

Bakail M, Ochsenbein F (2016) Targeting protein–protein interactions, a wide open field for drug design. C R Chim 19(1):19–27

Article  CAS  Google Scholar 

Bird GH et al (2016) Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nat Chem Biol 12(10):845–852

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boohaker RJ et al (2018) Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction. Cancer Lett 434:11–21

Article  PubMed  CAS  Google Scholar 

Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689

PubMed  CAS  Google Scholar 

Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: critical elements in the control of small G proteins. Cell 129(5):865–877

Article  PubMed  CAS  Google Scholar 

Bruzzoni-Giovanelli H et al (2018) Interfering peptides targeting protein-protein interactions: the next generation of Drugs? Drug Discov Today 23(2):272–285

Article  PubMed  CAS  Google Scholar 

Bullock BN, Jochim AL, Arora PS (2011) Assessing helical protein interfaces for inhibitor design. J Am Chem Soc 133(36):14220–14223

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burns MC et al (2014) Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A 111(9):3401–3406

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cao Q et al (2008) Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with Breast cancer. Eur J Nucl Med Mol Imaging 35(8):1489–1498

Article  PubMed  CAS  Google Scholar 

Chatterjee J et al (2008) N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res 41(10):1331–1342

Article  PubMed  CAS  Google Scholar 

Chatterjee J, Rechenmacher F, Kessler H (2013) N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl 52(1):254–269

Article  PubMed  CAS  Google Scholar 

Cho KJ, van der Hoeven D, Hancock JF (2013) Inhibitors of K-Ras plasma membrane localization Enzymes, 33 Pt A: p. 249 – 65

Deng Y, Li J (2017) Rational optimization of Tumor suppressor-derived peptide inhibitor selectivity between Oncogene Tyrosine Kinases ErbB1 and ErbB2. Arch Pharm 350(12):1700181

Article  Google Scholar 

Fairlie DP, Dantas de A, Araujo (2016) Rev Stapling Peptides Using Cysteine Crosslink Biopolymers 106(6):843–852

CAS  Google Scholar 

Ford B et al (2009) Characterization of a ras mutant with identical GDP-and GTP-bound structures. Biochemistry 48(48):11449–11457

Article  PubMed  CAS  Google Scholar 

Furet P et al (2019) Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence. Bioorg Med Chem Lett 29(16):2316–2319

Article  PubMed  CAS  Google Scholar 

Gabernet G et al (2019) In silico design and optimization of selective membranolytic anticancer peptides. Sci Rep 9(1):1–11

Article  CAS  Google Scholar 

Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55(6):1179–1188

Article  PubMed  CAS  Google Scholar 

Gunderwala AY et al (2019) Development of allosteric BRAF peptide inhibitors targeting the dimer interface of BRAF. ACS Chem Biol 14(7):1471–1480

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gupta UK, Mahanta S, Paul S (2013) Silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent. Med Hypotheses 81(5):853–861

Article  PubMed  CAS  Google Scholar 

Ho AL et al (2018) Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Ann Oncol 29:viii373

Article  Google Scholar 

Jing H et al (2016) Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy. Colloids Surf B Biointerfaces 146:387–395

Article  PubMed  CAS  Google Scholar 

Kamagata K et al (2019) Rational design using sequence information only produces a peptide that binds to the intrinsically disordered region of p53 Scientific reports, 9(1): p. 1–10

Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9(7):517–531

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kato K et al (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 89(14):6403–6407

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim YW, Grossmann TN, Verdine GL (2011) Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat Protoc 6(6):761–771

Article  PubMed  CAS  Google Scholar 

Lelle M et al (2015) Octreotide-mediated tumor-targeted drug delivery via a cleavable doxorubicin-peptide conjugate. Mol Pharm 12(12):4290–4300

Article  PubMed  CAS  Google Scholar 

Li Z, Buck M (2019) Computational design of myristoylated cell-penetrating peptides targeting oncogenic K-Ras. G12D at the effector-binding membrane interface. J Chem Inf Model 60(1):306–315

Article  Google Scholar 

Li HM et al (2017) De novo computational design for development of a peptide ligand oriented to VEGFR-3 with high affinity and long circulation. Mol Pharm 14(7):2236–2244

Article  PubMed  CAS  Google Scholar 

Lim KJ et al (2013) A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS ONE 8(6):e66084

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marqus S, Pirogova E, Piva TJ (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24(1):21

Article  PubMed  PubMed Central  Google Scholar 

Matsson P et al (2016) Cell permeability beyond the rule of 5. Adv Drug Deliv Rev 101:42–61

Article  PubMed  CAS  Google Scholar 

Nakajima EC et al (2022) FDA approval Summary: Sotorasib for KRAS G12C-Mutated metastatic NSCLC. Clin Cancer Res 28(8):1482–1486

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nevola L, Giralt E (2015) Modulating protein-protein interactions: the potential of peptides. Chem Commun (Camb) 51(16):3302–3315

Article  PubMed  CAS  Google Scholar 

Nomura TK et al (2021) Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains. Cell Chem Biology 28(11):1581–1589e6

Article  CAS  Google Scholar 

Novotny CJ et al (2017) Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative Prenylation to mislocalize K-Ras. ACS Chem Biol 12(7):1956–1962

Article  PubMed  PubMed Central  CAS  Google Scholar 

Oliveira S et al (2007) Fusogenic peptides enhance endosomal Escape improving siRNA-induced silencing of oncogenes. Int J Pharm 331(2):211–214

Article  PubMed  CAS  Google Scholar 

Ostrem JM et al (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548–551

Article  PubMed  PubMed Central  CAS  Google Scholar 

Papke B, Der CJ (2017) Drugging RAS: know the enemy. Science 355(6330):1158–1163

Article  PubMed